omniture
logo
Search
Duality Biotherapeutics
Media Room

Latest News

rss

Avenzo Therapeutics and DualityBio Announce Exclusive Global License for Potential Best-In-Class EGFR/HER3 Antibody-Drug Conjugate

Avenzo to receive exclusive global license (excluding Greater China) for development, manufacturing...

2025-01-07 22:00 1131
Avenzo Therapeutics and DualityBio Announce Exclusive Global License for Potential Best-In-Class EGFR/HER3 Antibody-Drug Conjugate

Duality Biologics Announces B7H4 ADC Milestone Achievement and License Exercise by BeiGene

SOMERSET, N.J., SHANGHAI and SUZHOU, China, Dec. 30, 2024 /PRNewswire/ -- Duality Biologics ("Duali...

2024-12-31 08:00 1769

Duality Biologics and GSK Enter Exclusive Option Agreement for a Novel Antibody-drug Conjugate (DB-1324)

PRINCETON, N.J., SHANGHAI and SUZHOU, China, Dec. 3, 2024 /PRNewswire/ -- Duality Biologics ("Duali...

2024-12-04 08:30 1172

Duality Biologics Announces Expansion of Adcendo ApS Collaboration Through Option Exercise of Strategic License Agreement

Adcendo ApS exercises its option to utilize Duality Biologics' platform to further enhance its firs...

2024-11-26 08:30 1172

DualityBio Expands Global Strategic Partnership with BioNTech to Accelerate Development of a Third Antibody-Drug Conjugate Therapeutics for Solid Tumors

SHANGHAI, Aug. 7, 2023 /PRNewswire/ -- Duality Biologics (Suzhou) Co. Ltd. ("DualityBio"), a clinic...

2023-08-07 18:00 1406

DualityBio Announces DB-1303 Granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for the Treatment of Advanced, Recurrent or Metastatic Endometrial Carcinoma with HER2 Overexpression

PRINCETON, N.J., SHANGHAI and SUZHOU, China, Jan. 20, 2023 /PRNewswire/ -- Duality Biologics ("Dual...

2023-01-20 18:00 3415

Duality Biologics Announces License Agreement of its Next-generation ADC platform with Adcendo

* Duality to grant license of DITAC (Duality Immune Toxin Antibody Conjugates) platform to Adcend...

2023-01-05 09:00 1347

Duality announced the appointment of Dr. Pasi A. Jänne as Member of SAB

PRINCETON, N. J., SHANGHAI and SUZHOU, China, Dec. 15, 2022 /PRNewswire/ -- Duality Biotherapeutics...

2022-12-15 21:00 1724
Duality announced the appointment of Dr. Pasi A. Jänne as Member of SAB

Duality announced the appointment of Dr. Yver as Chairman of SAB

PRINCETON, N. J. and SHANGHAI, SUZHOU, China, Oct. 3, 2022 /PRNewswire/ -- Duality Biotherapeutics,...

2022-10-03 22:00 1671
Duality announced the appointment of Dr. Yver as Chairman of SAB

Duality Biologics Completed $90 Million Series B Financing

PRINCETON, N.J. and SHANGHAI and SUZHOU, China, May 19, 2021 /PRNewswire/ -- Duality Biologics (Dua...

2021-05-20 08:00 1650